Clinical Benefits of an Adherence Monitoring Program in the Management of Secondary Hyperparathyroidism with Cinacalcet: Results of a Prospective Randomized Controlled Study

Abstract EN

Background/Aims.

One of the causes of uncontrolled secondary hyperparathyroidism (sHPT) is patient’s poor drug adherence.

We evaluated the clinical benefits of an integrated care approach on the control of sHPT by cinacalcet.

Methods.

Prospective, randomized, controlled, multicenter, open-label study.

Fifty hemodialysis patients on a stable dose of cinacalcet were randomized to an integrated care approach (IC) or usual care approach (UC).

In the IC group, cinacalcet adherence was monitored using an electronic system.

Results were discussed with the patients in motivational interviews, and drug prescription adapted accordingly.

In the UC group, drug adherence was monitored, but results were not available.

Results.

At six months, 84% of patients in the IC group achieved recommended iPTH targets versus 55% in the UC group (P=0.04).

The mean cinacalcet taking adherence improved by 10.8% in the IC group and declined by 5.3% in the UC group (P=0.02).

Concomitantly, the mean dose of cinacalcet was reduced by 7.2 mg/day in the IC group and increased by 6.4 mg/day in the UC group (P=0.03).

Conclusions.

The use of a drug adherence monitoring program in the management of sHPT in hemodialysis patients receiving cinacalcet improves drug adherence and iPTH control and allows a reduction in the dose of cinacalcet.